UniDoc Exclusively Licenses Technology for Global Markets

VANCOUVER, BC, — (June 9, 2022) – UniDoc Health Corp. (CSE: UDOC) (FRA: L7T) (OTCQB: UDOCF) (“UniDoc,” or the “Company”), an innovator in the telehealth sector, is pleased to announce it has amended its licensing agreement to encompass exclusive commercial activity worldwide.

On June 8, 2021, through its wholly owned subsidiary, UniCheck Holdings Corp. (UniCheck), the Company entered into a multi-year agreement with UniCheck S.R.L. of Italy to develop and commercialize certain UniCheck technologies and all intellectual property related thereto. Pursuant to this license agreement, UniCheck granted the Company an exclusive license to use the intellectual property rights, marks, know-how and technologies, including, the rights to make, have made, manufacture, produce, market, sell goods and services, distribute, import and export, and otherwise use the intellectual property rights and UniCheck technologies within North and South America.

Effective immediately, the amended agreement officially removes all territorial restrictions from the original agreement and grants UniCheck Holding and consequently UniDoc Health Corp. exclusive license to utilize and employ the UniCheck S.R.L. intellectual property globally. In particular, the Company will be, in connection with the Virtual Care Solutions Model, using software licensed and developed by UniCheck (such as, its cloud computing software), UniCheck’s designs of the physical booth and kiosk and other hardware (such as medical devices) designed and licensed by UniCheck S.R.L.

The Company and UniCheck S.R.L. also agreed collaborate on the development, improvement, marketing and selling of new products and services related to the UniCheck technologies. The amendment further grants Unicheck the non-exclusive and transferable license to improve upon UniCheck S.R.L intellectual property rights and to develop new intellectual property rights derived from the UniCheck technologies and the related intellectual property rights. The Company has the right to grant sublicenses of the rights, privileges and licenses granted within the License Agreement around the world.

UniDoc CEO Antonio Baldassarre notes, “We’re excited to make this licensing amendment official. As shown by our recent USA contract and with nationwide agreements in Ghana and Nigeria, the demand for accessible health care is demonstrably a global need. UniDoc is pleased to be able to offer our technology and services to the world market and anticipates additional global interest now that we are able to approach new market opportunities. From our perspective this is a significant milestone event that we hope will go a long way towards unlocking shareholder value as we continue to grow the business.”

On Behalf of The Board of Directors,

Sincerely,

~Antonio Baldassarre~

Antonio Baldassarre
CEO, President & Director
UniDoc Health Corp. (CSE: UDOC)

About UniDoc Health Corp. (CSE: UDOC) (FRA: L7T) (OTCQB: UDOCF)

UniDoc is developing a telehealth solution which is being designed as a self-contained remote virtual clinic within a private kiosk for patients to undergo full consultations as if they were present in a physician’s office. Telehealth opens the doors to a large segment of the population challenged by access, experience or understanding of online computer technology. It is the Company’s belief that physical accessibility is the key to its business proposition. UniDoc is dedicated to unlocking shareholder value by delivering an excellent product and sophisticated commercial network within an expedited timeframe. The UniDoc team encourages engagement, questions, and interest, so please stay in touch and invite anyone who might be interested in our story to visit our website at www.unidoctor.com and signup to receive the latest information with updates on our activities, events and progress. You are also invited to join us on social media with Facebook, Twitter or Instagram.

For further information, please contact

UniDoc Investor Relations
Tel: +1 778.383.6731
Email: info@unidoctor.com

Matt Chatterton, Director
Tel: +1 778.613.2082
Email: matt@unidoctor.com

Media Inquiries
media@unidoctor.com

Forward-Looking Statements

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the Company’s plans for the use of UniCheck’s intellectual property under the amended licensing agreement, the collaboration between the Company and UniCheck with respect to the improvement of UniCheck’s technologies, the anticipation of global interest in the Company’s products and the Company’s commercialization of the telehealth platform.

Forward-looking information is based on the assumptions, estimates, analysis, and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; the Company’s ability to secure additional financing on reasonable terms; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s  final prospectus dated December 2, 2021 under the heading “Risks Factors.” Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Sign Up For News Alerts

Enter your details below and we will add you to our News Alerts list.

Austin Thornberry

Director

Mr. Thornberry is a seasoned finance professional with a background in advising new companies in the venture capital market. He brings extensive experience working with high-growth companies across numerous industries through his past work in the technology and innovation banking group at the Bank of Montreal and in the financial services arm of Ernst & Young advising on multiple capital markets transactions. Mr. Thornberry has split his time working in Toronto, Ont., and Vancouver, B.C. He obtained his bachelor of commerce at McGill University and has held the CPA, CA, designation since 2019.

Matt Chatterton

DIRECTOR

Mr. Chatterton brings over 18 years of experience in development and execution of complex projects. His  expertise includes project management, facility management, logistics, and supply side processes and  procedures at a number of operations in Canada and internationally. He has  been involved in the public markets for the last three years managing IPO processes and transitioning  businesses to post listing operations. Mr. Chatterton is a Professional Engineer and graduate of  Canada’s Queens University with a Bachelor’s degree in Engineering Chemistry (2001) and Master’s degree in Chemical Process Engineering (2003).

Sina Pirooz

Director

Mr. Chatterton brings over 18 years of experience in development and execution of complex projects. His  expertise includes project management, facility management, logistics, and supply side processes and  procedures at a number of operations in Canada and internationally. He has  been involved in the public markets for the last three years managing IPO processes and transitioning  businesses to post listing operations. Mr. Chatterton is a Professional Engineer and graduate of  Canada’s Queens University with a Bachelor’s degree in Engineering Chemistry (2001) and Master’s degree in Chemical Process Engineering (2003).

Dr. Sazzad Hossain, PhD

Chief Scientific Officer

He is the former Chief Scientific Officer of InMed Pharmaceuticals Inc., a leading public Canadian bio-pharmaceutical company. Previously he worked as Senior Scientist at Biotechnology Research Institute of National Research Council Canada. Working with the Canadian government he helped establish the pharmacology laboratory to evaluate safety and efficacy of cannabinoid-based and other drugs under development for cancer, cardiovascular and ocular diseases.

Jacob Moshinsky

Chief Operating Officer

Jacob is the CEO & founder of MoviWear a GPS, fall down detection & remote vital-sign monitoring platform, alerting caregivers of real-time emergencies. Jacob is a communications and technology expert with over 15 years’ experience in the field. the NurtureWatch health monitoring Smartwatch and MoviWearMED remote vital sign monitoring platform Prior to MoviWear, Jacob worked in both the Canadian telecom and the CPG industry. He led the Product Development and Business Strategy team at TELUS for the Small Business Portfolio. Jacob also worked in various product and service management roles within Rogers Communications where he launched and managed wireless and wireline products.

Antonio Baldassarre

CEO, President and Director

Mr. Baldassarre has held senior management and director positions of new business start-ups and established multinational organizations with over 30 years of experience in the Security, Information Technology and Communications industries. With leadership skills in management of international operations, shareholder exit strategies, and overall business development, he has utilized a wide range of strategic programs to maximize organic growth into specific industry segments through OEM, alliances, and direct multi-level distribution channels.

Mr. Baldassarre is able to plan, organize and direct all aspects of a Corporation from Operations, P&L oversight, product distribution, Product promotions, sales and development activities and initiatives utilizing my extensive marketing/sales senior management experience with developed abilities in team leadership and program/campaign development. Directly involved in the growth, branding and ultimately optimizing market share, product awareness, revenues, profitability and shareholder value.

Mr. Baldassare is also the President of LRG Security Canada Inc. and LRG Security Europe.

Franco Staino

DIRECTOR

Mr. Franco Staino is a business professional with over 40 years experience in the pharmaceutical industry. Mr. Staino has significant experience in drug safety, traceability and anti-counterfeiting measures and has designed and implemented programs for the Italy National Health Service, the Ministry of Health and the Polygraphic Institute and State Mint.

Mr. Staino currently holds multiple positions including being the control representative of Carlucci a leading company engaged in the production of self-adhesive labels for consumer goods with high specialization for the pharmaceutical sector, and President of the Board of Directors of Topharmacia, a company that deals with the integral management of pharmacies throughout Italy in order to improve their ability to provide social and commercial services, to connect industrial marketing policy to that of the pharmacy, to offer tools in able to guarantee the financial balance of the companies involved.